GlassScriptPhysician profile
Sardar I Babar
NPI 1821194713
$20,906.59
in general payments reported to CMS, 2019-2025
52 companies · $8,081 in 2025
The $8,081 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,156 · 2020: $947 · 2021: $1,085 · 2022: $1,025 · 2023: $4,171 · 2024: $3,441 · 2025: $8,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $11K · Food and Beverage: $4,503 · Travel and Lodging: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $10,767.87 |
| Food and Beverage | $4,503.43 |
| Travel and Lodging | $422.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,146.66 | 2023-2025 | Ion, Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $1,508.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Covidien LP | $850.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $814.49 | 2019-2025 | Fasenra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $780.80 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $625.49 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Insmed, INC. | $580.00 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.94 | 2019-2025 | Ofev |
| Inspire Medical Systems, INC. | $387.14 | 2023-2024 | Inspire |
| Pulmonx Corporation | $376.84 | 2019-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Ethicon INC. | $350.18 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $328.77 | 2019-2025 | Winrevair, Keytruda, Zerbaxa |
| Grifols USA, LLC | $293.80 | 2019-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $229.18 | 2020-2025 | Acthar |
| Genzyme Corporation | $211.57 | 2019-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sardar Babar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.